Rucaparib,Nivolumab
BMS,clovis oncology
['rucaparib', 'ovarian', 'gyn', 'brca', 'biomarker']
another #parpi (rucaparib) is an effective maintenance in women with #ovariancancer after response to upfront chemotherapy! athena-mono as presented by dr. monk at #asco22 benefit was seen irrespective of biomarker- with greatest benefit in patients with brcam/hrd #gyncsm 
Gyn Onc at MD Anderson. She/Hers. Wife of @DrJasonWestin. Innovative clinical trials. #JCO social media editor. Opinions=mine.
https://t.co/QLXLDKSThc